12 月 5 日，Merus 公司宣布其开发的Bizengri（Zenocutuzumab) 生物制品许可申请 (BLA) 获得美国 FDA 批准上市，用于治疗神经调节蛋白 1 融合 (NRG1+) 非小细胞肺癌 (NSCLC) 和 NRG1+ ...

HLX11是复宏汉霖自主研发的帕妥珠单抗生物类似药，拟联合曲妥珠单抗和化疗用于早期乳腺癌及/或与原研药药品标签相符的其他适应症。2022年6月，复宏汉霖与Organon（欧加农）签订协议，授予其及其附属公司于除中国境内及港澳台地区以外全球范围内商业化 ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

据报道，礼来12月4日公告，替尔泊肽减肥版Zepound与司美格鲁肽减肥版Wegovy相比，实现了1.47倍的相对体重减轻。在第72周的临床研究中，针对肥胖或 ...

a HER2-targeted antibody that disrupts receptor heterodimerization between EGFR/HER2 and HER2/HER3; CP-751871, an IGF1R-targeted antibody; the IGF1R kinase inhibitor NVP-AEW541; and the mammalian ...

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

Figure 1. HER3 signaling boosts NSCLC cell growth and survival by forming heterodimers with EGFR, HER2, MET, AXL, or IGF-1R, activating multiple pathways. Image Credit: Sino Biological Inc.

HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

Researchers have hypothesised that inhibiting EGFR and HER3 in tandem could lead to greater ... AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which ...